Ansari Waseem Ahmad, Khan Mohsin Ali, Hasan S M Mahfooz, Siddiqui Zainab, Ahmad Saheem, Khan Mohd Shahnawaz, Khan Mohammad Faheem
Department of Biotechnology, Era's Lucknow Medical College & Hospital, Era University, Sarfarazganj, Hardoi Road, Lucknow, 226003 India.
Center for Disease Mapping and Therapeutic Research, Era's Lucknow Medical College & Hospital, Era University, Sarfarazganj, Hardoi Road, Lucknow, 226003 India.
3 Biotech. 2024 Oct;14(10):234. doi: 10.1007/s13205-024-04067-7. Epub 2024 Sep 16.
With the aim of finding the plant-derived allosteric inhibitors of caspase-3/-7, we conducted computational investigations of bioactive compounds present in various berry fruits. In a molecular docking study, perulactone demonstrated excellent binding affinity scores of -12.1 kcal/mol and -9.1 kcal/mol for caspase 7 and 3, respectively, whereas FDA-approved allosteric inhibitors (DICA and FICA) were found to show lower docking scores (-5.6 and -6.1 kcal/mol) against caspase 7 while (-5.0 and -5.1 kcal/mol) for caspase 3, respectively. MD simulations were used to validate the binding stability of perulactone in the active sites of caspase-7/-3, and the results showed outstanding stability with lower ligand RMSDs of 1.270-3.088 Å and 2.426-9.850 Å against the targeted receptor. Furthermore, we performed MMGBSA free binding energy, where the perulactone values of Δ were determined to be -63.98 kcal/mol and -66.32 kcal/mol for both receptors (3IBF and 1NME), which are significantly better than the -45.16 kcal/mol and -39.51 kcal/mol for DICA as well as -26.37 kcal/mol and -15.50 kcal/mol for FICA, respectively. The drug resemblance of perulactone was effectively evaluated by ADMET. Thus, our findings indicated that perulactone could be an orally administered therapeutic candidate for regulating apoptosis in a variety of disorders. However, there may be an urgent need to study using in vitro and in vivo experiments.
The online version contains supplementary material available at 10.1007/s13205-024-04067-7.
为了寻找植物来源的半胱天冬酶 -3/-7变构抑制剂,我们对各种浆果中存在的生物活性化合物进行了计算研究。在分子对接研究中,紫苏内酯对半胱天冬酶7和3的结合亲和力得分分别为 -12.1千卡/摩尔和 -9.1千卡/摩尔,而美国食品药品监督管理局批准的变构抑制剂(DICA和FICA)对半胱天冬酶7的对接得分较低(-5.6和 -6.1千卡/摩尔),对半胱天冬酶3的对接得分分别为(-5.0和 -5.1千卡/摩尔)。分子动力学模拟用于验证紫苏内酯在半胱天冬酶 -7/-3活性位点的结合稳定性,结果显示其稳定性出色,相对于靶向受体,配体的均方根偏差较低,分别为1.270 - 3.088 Å和2.426 - 9.850 Å。此外,我们进行了MMGBSA自由结合能计算,两种受体(3IBF和1NME)的紫苏内酯Δ值分别确定为 -63.98千卡/摩尔和 -66.32千卡/摩尔,这明显优于DICA的 -45.16千卡/摩尔和 -39.51千卡/摩尔以及FICA的 -26.37千卡/摩尔和 -15.50千卡/摩尔。通过ADMET有效地评估了紫苏内酯的药物相似性。因此,我们的研究结果表明,紫苏内酯可能是一种口服治疗候选药物,用于调节多种疾病中的细胞凋亡。然而,可能迫切需要进行体外和体内实验研究。
在线版本包含可在10.1007/s13205-024-04067-7获取的补充材料。